BR112013032421A2 - método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue - Google Patents
método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengueInfo
- Publication number
- BR112013032421A2 BR112013032421A2 BR112013032421A BR112013032421A BR112013032421A2 BR 112013032421 A2 BR112013032421 A2 BR 112013032421A2 BR 112013032421 A BR112013032421 A BR 112013032421A BR 112013032421 A BR112013032421 A BR 112013032421A BR 112013032421 A2 BR112013032421 A2 BR 112013032421A2
- Authority
- BR
- Brazil
- Prior art keywords
- dengue virus
- inducing
- infection
- immune response
- dengue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
resumo imunogenes indutores de linfócitos t citotóxicos para prevenção, tratamento e diagnóstico de infecção pelo vírus da dengue a dengue (df) e a dengue hemorrágica (dhr) são problemas de saúde pública globalmente significativos e o entendimento da resposta imune geral para a infecção irá contribuir para a administração adequada da doença e suas complicações potencialmente severas. vacinas vivas atenuadas e vacinas candidatas de subunidade, que estão sob avaliação clínica, induzem primeiramente uma resposta de anticorpo ao vírus e o mínimo de respostas de células t de reação cruzada. atualmente, não há ferramentas disponíveis para acessar as respostas de células t protetoras durante a infecção ou após a vacinação. a presente invenção incorpora imunoproteômicos para descobrir novos epítopos específicos de hla-a2 derivados de células infectadas pelo vírus da dengue (dv). tais epítopos são conservados com reação cruzada de ctls epítopo-específicos contra todos os quatro sorotipos de dv. tais epítopos possuem potencial como novas ferramentas de informação e de diagnóstico para caracterizar imunidade de célula t em infecção pelo vírus da dengue (dv), e serve como uma vacina candidata universal complementar às vacinas atuais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161502365P | 2011-06-29 | 2011-06-29 | |
PCT/US2012/044625 WO2013003579A1 (en) | 2011-06-29 | 2012-06-28 | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013032421A2 true BR112013032421A2 (pt) | 2017-01-17 |
Family
ID=47424544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013032421A BR112013032421A2 (pt) | 2011-06-29 | 2012-06-28 | método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue |
Country Status (5)
Country | Link |
---|---|
US (3) | US9637521B2 (pt) |
AU (1) | AU2012275319A1 (pt) |
BR (1) | BR112013032421A2 (pt) |
SG (2) | SG195115A1 (pt) |
WO (1) | WO2013003579A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012275319A1 (en) | 2011-06-29 | 2013-11-14 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of Dengue virus infection |
EP3228321B1 (en) | 2011-09-13 | 2019-04-10 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
WO2015175361A1 (en) * | 2014-05-13 | 2015-11-19 | Immunotope, Inc. | Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development |
TWI653049B (zh) * | 2016-10-21 | 2019-03-11 | 國立成功大學 | 合成多肽、包含該合成多肽之疫苗組合物及其用途 |
SG11202002044WA (en) | 2017-09-21 | 2020-04-29 | Emergex Vaccines Holding Ltd | MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus |
AU2019205627B2 (en) * | 2018-01-06 | 2024-05-09 | Emergex Vaccines Holding Limited | MHC class I associated peptides for prevention and treatment of multiple flavi virus |
US20220001001A1 (en) * | 2018-07-13 | 2022-01-06 | University Of Georgia Research Foundation | Broadly reactive immunogens of dengue virus, compositions, and methods of use thereof |
US11344614B2 (en) | 2018-09-29 | 2022-05-31 | Emergex Vaccines Holding Ltd. | Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes |
WO2021257770A2 (en) * | 2020-06-17 | 2021-12-23 | Tscan Therapeutics, Inc. | Sars-cov-2 immunodominant peptides and uses thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
EP1601947A2 (en) * | 2002-10-31 | 2005-12-07 | Health Research, Incorporated | Diagnostic test for west nile virus |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
WO2009152147A2 (en) * | 2008-06-09 | 2009-12-17 | La Jolla Institute For Allergy And Immunology | Compositions and methods for dengue virus (dv) treatment and vaccination |
AU2010286940A1 (en) | 2009-08-26 | 2012-03-08 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
GB201106069D0 (en) * | 2011-04-11 | 2011-05-25 | Isis Innovation | Peptide markers and uses thereof |
AU2012275319A1 (en) | 2011-06-29 | 2013-11-14 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of Dengue virus infection |
EP3228321B1 (en) | 2011-09-13 | 2019-04-10 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
-
2012
- 2012-06-28 AU AU2012275319A patent/AU2012275319A1/en not_active Abandoned
- 2012-06-28 SG SG2013086608A patent/SG195115A1/en unknown
- 2012-06-28 WO PCT/US2012/044625 patent/WO2013003579A1/en active Application Filing
- 2012-06-28 SG SG10201704908SA patent/SG10201704908SA/en unknown
- 2012-06-28 BR BR112013032421A patent/BR112013032421A2/pt not_active IP Right Cessation
- 2012-06-28 US US14/116,899 patent/US9637521B2/en active Active
-
2017
- 2017-03-28 US US15/471,098 patent/US10144766B2/en active Active
-
2018
- 2018-10-17 US US16/163,162 patent/US10556929B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170275338A1 (en) | 2017-09-28 |
SG10201704908SA (en) | 2017-07-28 |
SG195115A1 (en) | 2013-12-30 |
US10144766B2 (en) | 2018-12-04 |
US9637521B2 (en) | 2017-05-02 |
US20190106462A1 (en) | 2019-04-11 |
US10556929B2 (en) | 2020-02-11 |
WO2013003579A1 (en) | 2013-01-03 |
US20140105925A1 (en) | 2014-04-17 |
AU2012275319A1 (en) | 2013-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013032421A2 (pt) | método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue | |
Ku et al. | A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice | |
Ma et al. | Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines | |
Yu et al. | Pathogenic pseudorabies virus, China, 2012 | |
BR112017013891A2 (pt) | composições imunogênicas para uso em vacinas pneumocócicas | |
Liu et al. | Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
BR112022001185A2 (pt) | Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos | |
Blome et al. | Efficacy of marker vaccine candidate CP7_E2alf against challenge with classical swine fever virus isolates of different genotypes | |
Malavige et al. | T cell responses in dengue viral infections | |
BR112018007525A2 (pt) | composições imunogênicas de circovírus suíno tipo 3 e métodos de produzir e usar as mesmas | |
Chiang et al. | Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice | |
BR112014018815A8 (pt) | Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis | |
BR112013005427A2 (pt) | composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica. | |
Gong et al. | Immune responses and protective efficacy of a novel DNA vaccine encoding outer membrane protein of avian Pasteurella multocida | |
MX2020012913A (es) | Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas. | |
Chan et al. | Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine | |
Li et al. | Construction and immune protection evaluation of recombinant polyvalent OmpAs derived from genetically divergent ompA by DNA shuffling | |
BR112016026651A2 (pt) | evolução de vesículas semelhantes a vírus de alta titulação para aplicações de vacina | |
Leung et al. | An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus | |
BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
Zhang et al. | The pre-existing cellular immunity to Japanese encephalitis virus heterotypically protects mice from Zika virus infection | |
Lei et al. | Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus | |
Lu et al. | Immunopotentiators improve the efficacy of oil-emulsion-inactivated avian influenza vaccine in chickens, ducks and geese | |
Kulkarni et al. | Neutralizing antibody response and efficacy of novel recombinant tetravalent dengue DNA vaccine comprising envelope domain III in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |